{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:06:53Z","timestamp":1788887213494,"version":"build-2803163510"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":232,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP25K18921"],"award-info":[{"award-number":["JP25K18921"]}]},{"name":"JSPS KAKENHI","award":["JP24K10397"],"award-info":[{"award-number":["JP24K10397"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas with poor outcomes and limited therapeutic options. Although mitogen-activated protein kinase kinase (MEK) inhibitors are active in benign plexiform neurofibromas, their efficacy in MPNST treatment is modest. Enhancer of zeste homolog 2 (EZH2) inhibitors are preclinically efficacious in MPNST treatment, but their mechanisms of action remain unclear. We evaluated the therapeutic potential and molecular mechanism of combined EZH2 and MEK inhibitors in NF1-associated MPNST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Five human NF1-associated MPNST cell lines were exposed to EZH2 and\/or MEK inhibitors. Cell growth and apoptosis were quantified over time. Therapeutic efficacy was tested in a subcutaneous xenograft model. Proliferation and apoptosis in tumors were assessed using standard histologic markers, and intracellular localization of phosphorylated extracellular signal-regulated kinase (pERK) was examined using fluorescent immunohistochemistry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Monotherapy with EZH2 or MEK inhibitors reduced proliferation and increased apoptosis across all MPNST lines. Combination therapy produced greater tumor cell growth suppression and marked increases in apoptosis. In vivo, the combination significantly delayed tumor progression compared with monotherapy, with concomitant reductions in proliferative indices and increases in apoptotic indices. EZH2 inhibitor limited nuclear pERK entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dual EZH2 and MEK inhibitors yield additive antitumor activity in NF1-associated MPNST. Although the molecular mechanism could not be elucidated, our findings suggest that EZH2 inhibitors exhibited a polycomb repressive complex 2-independent, noncanonical mechanism characterized by pERK nuclear translocation restriction, providing a strong rationale for clinical evaluation of this combination in NF1-associated MPNST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag221","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:46:38Z","timestamp":1787226398000},"source":"Crossref","is-referenced-by-count":0,"title":["Combination of EZH2 and MEK inhibitors as an effective therapy for neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-0219","authenticated-orcid":false,"given":"Sogo","family":"Oki","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-2619","authenticated-orcid":false,"given":"Yukitomo","family":"Ishi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Natsumeda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Research Institute, University of Niigata , Niigata,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"Christine A","family":"Pratilas","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine , Baltimore, Maryland,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyuki","family":"Hakozaki","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine , Fukushima,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Division of Genome Biology, Institute for Genetic Medicine, Hokkaido University , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zen-ichi","family":"Tanei","sequence":"additional","affiliation":[{"name":"Department of Cancer Pathology, Hokkaido University Graduate School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hokkaido University Graduate School of Medicine , Sapporo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"2026090812112881900_vdag221-B1","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026090812112881900_vdag221-B2","doi-asserted-by":"publisher","first-page":"vdab033","DOI":"10.1093\/noajnl\/vdab033","article-title":"Malignant transformation of plexiform neurofibroma to MPNST while on MEK inhibitor","volume":"3","author":"Fasih","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026090812112881900_vdag221-B3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"2026090812112881900_vdag221-B4","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1017\/S1462399409001227","article-title":"Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways","volume":"11","author":"Katz","year":"2009","journal-title":"Expert Rev Mol Med."},{"key":"2026090812112881900_vdag221-B5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3171\/2015.12.JNS152443","article-title":"Patterns of recurrence and survival in sporadic, neurofibromatosis type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors","volume":"126","author":"Watson","year":"2017","journal-title":"J Neurosurg"},{"key":"2026090812112881900_vdag221-B6","doi-asserted-by":"publisher","first-page":"903177","DOI":"10.3389\/fonc.2022.903177","article-title":"Preclinical assessment of MEK inhibitors for malignant peripheral nerve sheath tumors reveals differences in efficacy and adaptive response","volume":"12","author":"Gu","year":"2022","journal-title":"Front Oncol"},{"key":"2026090812112881900_vdag221-B7","doi-asserted-by":"publisher","first-page":"E8","DOI":"10.3171\/2009.11.FOCUS09221","article-title":"Neurofibromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications","volume":"28","author":"Gottfried","year":"2010","journal-title":"Neurosurg Focus"},{"key":"2026090812112881900_vdag221-B8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60761-795-2_1","article-title":"The MAP kinase signaling Cascades: a system of hundreds of components regulates a diverse array of physiological functions","volume":"661","author":"Keshet","year":"2010","journal-title":"Methods Mol Biol"},{"key":"2026090812112881900_vdag221-B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1947601911407328","article-title":"The ERK Cascade: distinct functions within various subcellular organelles","volume":"2","author":"Wortzel","year":"2011","journal-title":"Genes Cancer"},{"key":"2026090812112881900_vdag221-B10","doi-asserted-by":"publisher","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","article-title":"MAP kinase pathways","volume":"4","author":"Morrison","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026090812112881900_vdag221-B11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2026090812112881900_vdag221-B12","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026090812112881900_vdag221-B13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090812112881900_vdag221-B14","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.1200\/JCO.2018.36.15_suppl.10503","article-title":"Sprint: phase II study of the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)","volume":"36","author":"Gross","year":"2018","journal-title":"JCO"},{"key":"2026090812112881900_vdag221-B15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.critrevonc.2019.04.007","article-title":"Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside","volume":"138","author":"Martin","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026090812112881900_vdag221-B16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/1535-7163.MCT-13-0189","article-title":"NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition","volume":"12","author":"Dodd","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2026090812112881900_vdag221-B17","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","article-title":"Combined inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res"},{"key":"2026090812112881900_vdag221-B18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/genes11030331","article-title":"Kinome profiling of NF1-related MPNSTs in response to kinase inhibition and doxorubicin reveals therapeutic vulnerabilities","volume":"11","author":"Grit","year":"2020","journal-title":"Genes (Basel)"},{"key":"2026090812112881900_vdag221-B19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/0008-5472.CAN-20-1992","article-title":"Activation of receptor tyrosine kinases mediates acquired resistance to MEK inhibition in malignant peripheral nerve sheath tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"2026090812112881900_vdag221-B20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2026090812112881900_vdag221-B21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10555-012-9387-3","article-title":"EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis","volume":"31","author":"Crea","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"2026090812112881900_vdag221-B22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet"},{"key":"2026090812112881900_vdag221-B23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"De Raedt","year":"2014","journal-title":"Nature"},{"key":"2026090812112881900_vdag221-B24","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ng.3116","article-title":"Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat Genet"},{"key":"2026090812112881900_vdag221-B25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-015-0325-1","article-title":"Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway","volume":"14","author":"Zhang","year":"2015","journal-title":"Mol Cancer"},{"key":"2026090812112881900_vdag221-B26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/path.4294","article-title":"EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesis","volume":"232","author":"Zhang","year":"2014","journal-title":"J Pathol"},{"key":"2026090812112881900_vdag221-B27","doi-asserted-by":"publisher","first-page":"eadg8876","DOI":"10.1126\/sciadv.adg8876","article-title":"CDK4\/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors","volume":"9","author":"Wang","year":"2023","journal-title":"Sci Adv"},{"key":"2026090812112881900_vdag221-B28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41597-020-0508-5","article-title":"A clinically and genomically annotated nerve sheath tumor biospecimen repository","volume":"7","author":"Pollard","year":"2020","journal-title":"Sci Data"},{"key":"2026090812112881900_vdag221-B29","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/neuonc\/noad097","article-title":"Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology","volume":"25","author":"Larsson","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026090812112881900_vdag221-B30","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00428-009-0848-1","article-title":"Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2","volume":"455","author":"Hakozaki","year":"2009","journal-title":"Virchows Arch"},{"key":"2026090812112881900_vdag221-B31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026090812112881900_vdag221-B32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"2026090812112881900_vdag221-B33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1158\/1535-7163.MCT-21-0646","article-title":"Therapeutic targeting of EZH2 and BET BRD4 in pediatric rhabdoid tumors","volume":"21","author":"Ishi","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2026090812112881900_vdag221-B34","doi-asserted-by":"publisher","first-page":"03.25.585959","DOI":"10.1101\/2024.03.25.585959","article-title":"Pharmacogenomic synthetic lethal screens reveal hidden vulnerabilities and new therapeutic approaches for treatment of NF1-associated tumors","volume":"2024","author":"Williams","year":"2024","journal-title":"bioRxiv"},{"key":"2026090812112881900_vdag221-B35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/1471-2407-13-224","article-title":"Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-\u03b2","volume":"13","author":"Ohishi","year":"2013","journal-title":"BMC Cancer"},{"key":"2026090812112881900_vdag221-B36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41467-024-44755-9","article-title":"Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance","volume":"15","author":"Vasudevan","year":"2024","journal-title":"Nat Commun"},{"key":"2026090812112881900_vdag221-B37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/genes11030287","article-title":"The role of polycomb repressive complex in malignant peripheral nerve sheath tumor","volume":"11","author":"Zhang","year":"2020","journal-title":"Genes (Basel)"},{"key":"2026090812112881900_vdag221-B38","doi-asserted-by":"publisher","first-page":"10128","DOI":"10.1038\/s41598-025-94517-w","article-title":"The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors","volume":"15","author":"Soukar","year":"2025","journal-title":"Sci Rep"},{"key":"2026090812112881900_vdag221-B39","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-21-3760","article-title":"The need for new treatments targeting MPNST: the potential of strategies combining MEK inhibitors with antiangiogenic agents","volume":"28","author":"Gonz\u00e1lez-Mu\u00f1oz","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026090812112881900_vdag221-B40","doi-asserted-by":"publisher","first-page":"57171","DOI":"10.18632\/oncotarget.11036","article-title":"Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors","volume":"7","author":"Ahsan","year":"2016","journal-title":"Oncotarget"},{"key":"2026090812112881900_vdag221-B41","doi-asserted-by":"publisher","first-page":"e432242","DOI":"10.1200\/EDBK_432242","article-title":"Contemporary approach to neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"44","author":"Hirbe","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026090812112881900_vdag221-B42","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1158\/1078-0432.CCR-24-1750","article-title":"MEK inhibitors lead to PDGFR pathway upregulation and sensitize tumors to RAF dimer inhibitors in NF1-deficient malignant peripheral nerve sheath tumor","volume":"30","author":"Miranda-Rom\u00e1n","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090812112881900_vdag221-B43","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/ijms21041548","article-title":"Combined targeting of AKT and mTOR inhibits proliferation of human NF1-associated malignant peripheral nerve sheath tumour cells in vitro but not in a xenograft mouse model in vivo","volume":"21","author":"Schulte","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026090812112881900_vdag221-B44","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-23-0749","article-title":"CDK4\/6-MEK inhibition in MPNSTs causes plasma cell infiltration, sensitization to PD-L1 blockade, and tumor regression","volume":"29","author":"Kohlmeyer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026090812112881900_vdag221-B45","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-22-3722","article-title":"MEK inhibition synergizes with TYK2 inhibitors in NF1-associated malignant peripheral nerve sheath tumors","volume":"29","author":"Borcherding","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026090812112881900_vdag221-B46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12032-023-02025-6","article-title":"The roles of EZH2 in cancer and its inhibitors","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol"},{"key":"2026090812112881900_vdag221-B47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat Res"},{"key":"2026090812112881900_vdag221-B48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/PAS.0000000000000564","article-title":"Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST","volume":"40","author":"Prieto-Granada","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"2026090812112881900_vdag221-B49","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1242\/dev.107078","article-title":"Nuclear to cytoplasmic shuttling of ERK promotes differentiation of muscle stem\/progenitor cells","volume":"141","author":"Michailovici","year":"2014","journal-title":"Development"},{"key":"2026090812112881900_vdag221-B50","doi-asserted-by":"publisher","first-page":"16345","DOI":"10.1038\/s41598-017-16558-0","article-title":"Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells","volume":"7","author":"Arafeh","year":"2017","journal-title":"Sci Rep"},{"key":"2026090812112881900_vdag221-B51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"2026090812112881900_vdag221-B52","doi-asserted-by":"publisher","first-page":"e0183155","DOI":"10.1371\/journal.pone.0183155","article-title":"Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors","volume":"12","author":"Amirnasr","year":"2017","journal-title":"PLoS One"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag221\/70757928\/vdag221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag221\/70757928\/vdag221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag221\/70757928\/vdag221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:12:08Z","timestamp":1788883928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag221\/8767776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag221","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag221"}}